逍遥散及其化裁方治疗慢性乙型病毒性肝炎的临床研究进展
Clinical Research Progress on Xiaoyao San and Its Modified Formulas in the Treatment of Chronic Hepatitis B Virus Infection
DOI: 10.12677/TCM.2023.1212517, PDF, 下载: 83  浏览: 139 
作者: 文 青：成都中医药大学临床医学院，四川 成都；陈 婧：成都中医药大学附属医院，四川 成都
关键词: 逍遥散；慢性乙型病毒性肝炎；作用机制；中医药治疗；综述；Xiaoyao San； Chronic Hepatitis B Virus Infection； Mechanism of Action； Traditional Chinese Medicine Treatment； Review
摘要: 慢性乙型病毒性肝炎(CHB)，归于中医学“胁痛”“郁证”等范畴，是一种临床常见的感染性疾病，是肝硬化、肝细胞癌和肝衰竭的主要原因。逍遥散出自《太平惠民和剂局方》，由柴胡、当归、白芍、白术、茯苓、煨姜、薄荷、炙甘草组成，具有疏肝解郁、养血健脾的功效。目前已经有大量的基础研究及临床研究证明了逍遥散及其化裁方用于治疗CHB有良好的疗效，患者依从性高，无明显不良反应。本文通过整理相关文献，对逍遥散及其化裁方治疗CHB的理论基础、临床应用和基础作用机制等进行了综合分析，以期为逍遥散及其化裁方运用于临床提供参考与指导，同时也为逍遥散治疗CHB的作用机制的深入研究提供更多的思路，为逍遥散的研发提供更多方向和选择。
Abstract: Chronic hepatitis B virus infection (CHB), classified under the categories of “Xie Tong” and “Yu Zheng” in traditional Chinese medicine, is a common clinical infectious disease and a major cause of liver cirrhosis, hepatocellular carcinoma, and liver failure. Xiaoyao San, originating from the Taiping Hui Min He Ji Ju Fang (《太平惠民和剂局方》) is composed of Bupleurum, Chinese angelica (Danggui), white peony (Baishao), white atractylodes (Baizhu), poria (Fuling), ginger, peppermint, and licorice. It possesses the ability to soothe the liver, relieve stagnation, nourish blood, and invigorate the spleen. Numerous studies, both in basic research and clinical settings, have demonstrated the positive therapeutic effects of Xiaoyao San and its modified formulations in the treatment of CHB. Patients exhibit high compliance with minimal adverse reactions. This article reviews relevant literature, comprehensively analyzing the theoretical basis, clinical application, and underlying mechanisms of Xiaoyao San and its modified formulations in the treatment of CHB. The aim is to provide guidance and references for the clinical application of Xiaoyao San and stimulate further research into its mechanisms of action in treating CHB, offering more insights for the development of Xiaoyao San in various directions.
文章引用：文青, 陈婧. 逍遥散及其化裁方治疗慢性乙型病毒性肝炎的临床研究进展[J]. 中医学, 2023, 12(12): 3473-3481. https://doi.org/10.12677/TCM.2023.1212517

参考文献

[1] Martinez, M.G., Boyd, A., Combe, E., Testoni, B. and Zoulim, F. (2021) Covalently Closed Circular DNA: The Ultimate Therapeutic Target for Curing Hepatitis B Virus Infections. Journal of Hepatology, 75, 706-717.
https://doi.org/10.1016/j.jhep.2021.05.013
[2] Tang, L.S.Y., Covert, E., Wilson, E. and Kottilil, S. (2018) Chronic Hepatitis B Infection: A Review. The Journal of the American Medical Association, 319, 1802-1813.
https://doi.org/10.1001/jama.2018.3795
[3] Liu, J., Liang, W., Jing, W. and Liu, M. (2019) Countdown to 2030: Eliminating Hepatitis B Disease, China. Bulletin of the World Health Organization, 97, 230-238.
https://doi.org/10.2471/BLT.18.219469
[4] 中国疾病预防控制中心传染病预防控制处. 2022年3月中国甲乙丙类传染病疫情动态概要[J]. 疾病监测, 2022, 37(4): 422-423.
[5] Rui, Y., Fan, R. and Hou, J. (2014) Chronic Hepatitis B Virus Infection: Epidemiology, Prevention, and Treatment in China. Frontiers of Medicine, 8, 135-144.
https://doi.org/10.1007/s11684-014-0331-5
[6] 中华中医药学会肝胆病专业委员会. 慢性乙型肝炎中医诊疗指南(2018年版) [J]. 中西医结合肝病杂志, 2019, 29(1): 97-102.
[7] 陈少芳, 郭明章, 鲁玉辉. 慢性乙型肝炎中医证型分布规律探析[J]. 福建中医药大学学报, 2014, 24(6): 1-3, 6.
[8] 卓锦蓝, 龚先琼. 慢性乙型肝炎中医证型研究[J]. 医学信息, 2020, 33(3): 43-45.
[9] 李卓娴, 徐丽静, 夏猛. 逍遥散类方治疗肝癌的研究进展[J]. 环球中医药, 2022, 15(8): 1491-1496.
[10] 陈师文, 辑. 太平惠民和剂局方[M]. 北京: 人民卫生出版社, 1962: 164.
[11] 李红香, 戴慎. 逍遥散之溯源[J]. 吉林中医药, 2010, 30(6): 522-523.
[12] 赵献可. 医贯[M]. 郭君双, 整理. 北京: 人民卫生出版社, 2005: 135.
[13] (汉)张仲景. 金匮要略[M]. 何任, 何若苹, 整理. 北京: 人民卫生出版社, 2005: 3.
[14] 张介宾. 中医临床必读丛书: 景岳全书[M]. 李继明, 整理. 北京: 中国中医药出版社, 2007: 1398, 1673.
[15] 黄帝内经素问[M]. 王冰, 注. 北京: 人民卫生出版社, 2002: 212.
[16] Ma, H.Y., Dong, L., Quan, S.Z., Li, R.Y. and Wang, X.R. (2021) Comparison of Four Markers of Hepatic Fibrosis and Hepatic Function Indices in Patients with Liver Cirrhosis and Hepatoma. Annals of Palliative Medicine, 10, 4108-4121.
https://doi.org/10.21037/apm-20-1623
[17] 任高阳. 加减逍遥散治疗肝郁气滞型乙型肝炎的效果观察及有效率影响分析[J]. 临床医药文献电子杂志, 2020, 7(47): 161-162.
[18] 郑婕. 逍遥散配合复方甘草酸苷治疗慢性乙型肝炎发生的作用探讨[J]. 中国医药指南, 2019, 17(3): 170-171.
[19] 张莹, 聂红明, 汪蓉, 等. 乙型肝炎及其慢性化机制研究进展[J]. 中西医结合肝病杂志, 2021, 31(6): 569-573.
[20] Tu, T. and Douglas, M.W. (2020) Hepatitis B Virus Infection: From Diagnostics to Treatments. Viruses, 12, Article 1366.
https://doi.org/10.3390/v12121366
[21] 王琛, 张永乐, 潘克女, 等. 慢性乙型肝炎患者外周血TRECs与CD45T淋巴细胞亚群检测的临床意义[J]. 中国现代医生, 2018, 56(23): 8-11.
[22] 李洪. 逍遥散联合阿德福韦酯对慢性乙肝患者细胞免疫功能的影响[J]. 中外医学研究, 2013, 11(24): 39-40.
[23] 廖雪姣, 吴其恺, 邓欣, 等. 恩替卡韦联合柴胡疏肝散对CHB的治疗作用及对患者外周血调节性T细胞水平的影响[J]. 临床医学工程, 2019, 26(4): 491-492.
[24] Vu, T.T.M., Le, T.V., Dang, A.K., et al. (2019) Socioeconomic Vulnerability to Depressive Symptoms in Patients with Chronic Hepatitis B. International Journal of Environmental Research and Public Health, 16, Article 255.
https://doi.org/10.3390/ijerph16020255
[25] Beurel, E., Toups, M. and Nemeroff, C.B. (2020) The Bidirectional Relationship of Depression and Inflammation: Double Trouble. Neuron, 107, 234-256.
https://doi.org/10.1016/j.neuron.2020.06.002
[26] 郑琴, 孔祥文, 孙文军, 等. 逍遥散治疗肝郁脾虚型混合性焦虑抑郁障碍的临床疗效[J]. 临床药物治疗杂志, 2021, 19(7): 60-64.
[27] 陈孔树, 陈明, 吴祖美, 等. 逍遥散配合米氮平片治疗精神分裂症后抑郁的临床效果[J]. 中外医学研究, 2021, 19(24): 144-146.
[28] 利永聪, 李建娴, 梁明坤, 等. 柴胡疏肝散治疗卒中后抑郁肝气郁结证临床研究[J]. 辽宁中医药大学学报, 2022, 24(6): 76-79.
[29] Roehlen, N., Crouchet, E. and Baumert, T.F. (2020) Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells, 9, Article 875.
https://doi.org/10.3390/cells9040875
[30] 王万娥, 张青, 王雨露, 等. 逍遥散加减联合替诺福韦治疗慢性乙肝肝纤维化(肝郁脾虚证)临床观察[J]. 湖北中医药大学学报, 2022, 24(5): 28-31.
[31] 韩方方. 逍遥散联合抗病毒治疗肝郁脾虚证乙型肝炎的效果及对肝纤维化的影响[J]. 大医生, 2022, 7(21): 89-91.
[32] 杨梦迪, 王学红. 慢性乙肝患者肠道菌群紊乱的研究现状[J]. 世界最新医学信息文摘, 2018, 18(55): 87-88.
https://doi.org/10.19613/j.cnki.1671-3141.2018.55.037
[33] 宋小平, 陈显韬, 敬秀平. 加味逍遥散联合双歧杆菌三联活菌胶囊治疗肠易激综合征的临床疗效及对肠道微生态功能的影响[J]. 解放军医药杂志, 2020, 32(2): 84-87, 92.
[34] 缪亚兰. 逍遥散的药理研究概况[J]. 中国处方药, 2014, 12(9): 141-142.
[35] Li, C., Liu, S., Zheng, J. and Xue, Y. (2021) Angelica Sinensis Polysaccharide (ASP) Attenuates Diosbulbin-B (DB)- Induced Hepatotoxicity through Activating the MEK/ERK Pathway. Bioengineered, 12, 3516-3524.
https://doi.org/10.1080/21655979.2021.1950280
[36] 任敏霞, 吴素香, 詹淑玉, 等. 白芍总苷及其所含主要成分芍药苷和芍药内酯苷对四氯化碳致小鼠急性肝损伤的保护作用[J]. 中华中医药学刊, 2020, 38(5): 244-247, 283.
[37] 程玥, 丁泽贤, 张越, 等. 不同茯苓提取物对急性肝损伤小鼠的保护作用[J]. 安徽中医药大学学报, 2020, 39(4): 73-77.
[38] Tan, M., Bhadoria, A.S., et al. (2021) Estimating the Proportion of People with Chronic Hepatitis B Virus Infection Eligible for Hepatitis B Antiviral Treatment Worldwide: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology and Hepatology, 6, 106-119.
https://doi.org/10.1016/S2468-1253(20)30307-1
[39] Iannacone, M. and Guidotti, L.G. (2022) Immunobiology and Pathogenesis of Hepatitis B Virus Infection. Nature Reviews Immunology, 22, 19-32.
https://doi.org/10.1038/s41577-021-00549-4
[40] 霍瑞静, 张翠丽, 李静, 等. 柴胡疏肝散对HBV感染小鼠Th17/Treg细胞亚群失衡的逆转作用[J]. 中华医院感染学杂志, 2021, 31(14): 2129-2133.
[41] 汪娟, 王芳. 白芍总苷治疗自身免疫性疾病的研究进展[J]. 医学综述, 2021, 27(22): 4481-4485.
[42] Giadans, C.G., Ríos, D.A., Ameigeiras, B., et al. (2019) Chronic Hepatitis B: The Interplay between Intrahepatic Lymphocyte Population and Viral Antigens in Relation to Liver Damage. Journal of Viral Hepatitis, 26, 727-737.
https://doi.org/10.1111/jvh.13078
[43] Woziwodzka, A., Rybicka, M., Sznarkowska, A., Romanowski, T., Dręczewski, M., Stalke, P. and Bielawski, K.P. (2019) TNF-α Polymorphisms Affect Persistence and Progression of HBV Infection. Molecular Genetics & Genomic Medicine, 7, e00935.
https://doi.org/10.1002/mgg3.935
[44] Zhou, Y., Jin, L., Kong, F., et al. (2016) Clinical and Immunological Consequences of Total Glucosides of Paeony Treatment in Sjögren’s Syndrome: A Randomized Controlled Pilot Trial. International Immunopharmacology, 39, 314-319.
https://doi.org/10.1016/j.intimp.2016.08.006
[45] 郝健亨, 陈浩, 高艳, 等. 柴胡皂苷d对自身免疫性肝炎小鼠差异表达基因CTLA-4、IL-10和IL-17的影响[J]. 上海交通大学学报(医学版), 2020, 40(3): 303-309.
[46] 李敏, 高凯, 王华林, 等. 柴胡皂苷d-黄芩苷配伍对CCl_4诱导大鼠HSC的TLR4-NF-κB通路作用研究[J]. 陕西中医, 2018, 39(1): 3-5.
[47] Marwaha, S., Palmer, E., Suppes, T., Cons, E., Young, A.H. and Upthegrove, R. (2023) Novel and Emerging Treatments for Major Depression. The Lancet, 401, 141-153.
https://doi.org/10.1016/S0140-6736(22)02080-3
[48] 梁文青, 程凯, 巩子汉, 等. 逍遥散抗抑郁的药理学机制研究进展[J]. 环球中医药, 2022, 15(11): 2243-2249.
[49] Cao, G.P., Gui, D., Fu, L.D., Guo, Z.K. and Fu, W.J. (2016) Anxiolytic and Neuroprotective Effects of the Traditional Chinese Medicinal Formulation Dan-Zhi-Xiao-Yao-San in a Rat Model of Chronic Stress. Molecular Medicine Reports, 14, 1247-1254.
https://doi.org/10.3892/mmr.2016.5382
[50] 程金来, 温小雨, 孙玉浩, 等. 加味逍遥散对肝癌大鼠脑内多巴胺和5-羟色胺水平的影响[J]. 神经解剖学杂志, 2020, 36(2): 144-148.
[51] 周薏, 葛冰景, 肖铁刚, 等. 逍遥散及其功效拆方对慢性铁过载诱导的肝纤维化的影响[J]. 云南中医学院学报, 2021, 44(1): 17-23, 41.
[52] 翁飞鸿, 周一平, 伊思敏, 等. 肝纤维化的病理学发生机制及诊疗研究进展[J]. 天津医科大学学报, 2023, 29(5): 559-563.
[53] 陈曦, 牟璐璐, 陈丹丹, 等. 逍遥散对肝纤维化大鼠模型抗纤维化作用及其机制研究[J]. 中药新药与临床药理, 2014, 25(3): 241-244.
[54] 余学竟, 赖国权, 韦翠, 等. 基于网络大数据研究逍遥散治疗肝纤维化的作用机制[J]. 中华中医药学刊, 2021, 39(1): 110-114, 282-284.
[55] Yang, X.A., Lv, F., et al. (2020) Potential Role of Intestinal Microflora in Disease Progression among Patients with Different Stages of Hepatitis B. Gut Pathogens, 12, Article No. 50.
https://doi.org/10.1186/s13099-020-00391-4
[56] 陈斌, 徐嘉蔚, 彭杰, 等. 基于逍遥散及其拆方研究“肝病实脾法”对肝纤维化大鼠肠道菌群的影响[J]. 临床肝胆病杂志, 2016, 32(4): 657-662.
[57] 吴佳佳. 逍遥散对肠道菌群失调小鼠神经炎症及结肠上皮屏障的保护作用[D]: [博士学位论文]. 北京: 北京中医药大学, 2020.